(Q33659004)

28 July 2017

title

Treatment of psoriatic arthritis in a phase 3 randomised, placebo-controlled trial with apremilast, an oral phosphodiesterase 4 inhibitor (English)

1 reference

28 July 2017

main subject

phase III clinical trial

0 references

placebo

0 references

apremilast

1 reference

ChEBI release 2020-05-28

1 reference

placebo-controlled trial

1 reference

11

Douglas Hough

1 reference

28 July 2017

6

Dafna D Gladman

1 reference

28 July 2017

13

Georg Schett

1 reference

28 July 2017

1

Arthur Kavanaugh

1 reference

28 July 2017

Philip J Mease

2

1 reference

28 July 2017

Juan J Gomez-Reino

3

1 reference

28 July 2017

Adewale O Adebajo

4

1 reference

28 July 2017

Jürgen Wollenhaupt

5

1 reference

28 July 2017

Eric Lespessailles

7

1 reference

28 July 2017

Stephen Hall

8

1 reference

28 July 2017

Marla Hochfeld

9

1 reference

28 July 2017

ChiaChi Hu

10

1 reference

28 July 2017

Randall M Stevens

12

1 reference

28 July 2017

language of work or name

English

0 references

publication date

4 March 2014

1 reference

Annals of the Rheumatic Diseases

28 July 2017

published in

1 reference

28 July 2017

volume

73

1 reference

28 July 2017

issue

6

1 reference

28 July 2017

page(s)

1020-1026

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4033106

28 July 2017

1 reference

A randomized placebo-controlled trial of methotrexate in psoriatic arthritis

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4033106

European League Against Rheumatism recommendations for the management of psoriatic arthritis with pharmacological therapies

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4033106

A systematic literature review of drug therapies for the treatment of psoriatic arthritis: current evidence and meta-analysis informing the EULAR recommendations for the management of psoriatic arthritis

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4033106

Apremilast, a cAMP phosphodiesterase-4 inhibitor, demonstrates anti-inflammatory activity in vitro and in a model of psoriasis

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4033106

Guidelines of care for the management of psoriasis and psoriatic arthritis: section 4. Guidelines of care for the management and treatment of psoriasis with traditional systemic agents.

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4033106

Psoriatic arthritis: epidemiology, clinical features, course, and outcome

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4033106

Apremilast mechanism of action and application to psoriasis and psoriatic arthritis

21 June 2018

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2013-205056

American College of Rheumatology. Preliminary definition of improvement in rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2013-205056

Efficacy and safety of ustekinumab in patients with active psoriatic arthritis: 1 year results of the phase 3, multicentre, double-blind, placebo-controlled PSUMMIT 1 trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2013-205056

Golimumab, a new human tumor necrosis factor alpha antibody, administered every four weeks as a subcutaneous injection in psoriatic arthritis: Twenty-four-week efficacy and safety results of a randomized, placebo-controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2013-205056

Classification criteria for psoriatic arthritis: development of new criteria from a large international study

21 January 2018

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/24595547

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

The Swedish early psoriatic arthritis register-- 2-year followup: a comparison with early rheumatoid arthritis

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/24595547

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Oral apremilast in the treatment of active psoriatic arthritis: results of a multicenter, randomized, double-blind, placebo-controlled study

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/24595547

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.1136/ANNRHEUMDIS-2013-205056

1 reference

28 July 2017

1 reference

28 July 2017

1 reference